Shanghai Runda Medical Technology Co Ltd
SSE:603108

Watchlist Manager
Shanghai Runda Medical Technology Co Ltd Logo
Shanghai Runda Medical Technology Co Ltd
SSE:603108
Watchlist
Price: 17.31 CNY -0.46%
Market Cap: 10.4B CNY
Have any thoughts about
Shanghai Runda Medical Technology Co Ltd?
Write Note

Shanghai Runda Medical Technology Co Ltd
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shanghai Runda Medical Technology Co Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Shanghai Runda Medical Technology Co Ltd
SSE:603108
Cash from Operating Activities
ÂĄ753.7m
CAGR 3-Years
83%
CAGR 5-Years
11%
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Cash from Operating Activities
ÂĄ11.4B
CAGR 3-Years
34%
CAGR 5-Years
36%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Cash from Operating Activities
ÂĄ2.5B
CAGR 3-Years
9%
CAGR 5-Years
24%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Cash from Operating Activities
ÂĄ3.2B
CAGR 3-Years
13%
CAGR 5-Years
30%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Cash from Operating Activities
ÂĄ1.1B
CAGR 3-Years
-4%
CAGR 5-Years
15%
CAGR 10-Years
37%
W
WuXi XDC Cayman Inc
HKEX:2268
Cash from Operating Activities
ÂĄ332.8m
CAGR 3-Years
262%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shanghai Runda Medical Technology Co Ltd
Glance View

Market Cap
10.4B CNY
Industry
Life Sciences Tools & Services

Shanghai Runda Medical Technology Co Ltd, nestled in the bustling heart of China's economic capital, stands as a quintessential example of a company thriving at the crossroads of innovation and healthcare. Established as a key player in medical diagnostics, Runda Medical focuses on the distribution and provision of high-quality medical devices and diagnostic solutions. Their business model revolves around integrating advanced technology with healthcare needs, enabling medical institutions to enhance their diagnostics capabilities through cutting-edge equipment and robust system support. The company holds a substantial portfolio of both proprietary and partnered products, allowing healthcare providers faster and more precise diagnostic insights. This is bolstered by a dependable supply chain and comprehensive after-sales service, ensuring that medical institutions can rely on consistent performance from their systems. Runda Medical's financial engine is powered predominantly by its distribution networks and strategic partnerships with leading medical technology firms worldwide. By leveraging these alliances, the company can offer a wide range of products that serve various segments of the medical industry, including hospitals, clinics, and laboratories. Revenue flows are primarily generated through the sale of medical devices such as automated analyzers, imaging systems, and diagnostic reagents — all designed to meet the growing demands for efficiency and accuracy in healthcare diagnosis. Moreover, their value proposition is further enhanced by the company's investments in customer education and training, ensuring that the end-users of their systems are not just purchasers but long-term partners in progress, thereby solidifying Runda Medical's reputation as a steadfast ally in China's healthcare landscape.

Intrinsic Value
28.91 CNY
Undervaluation 40%
Intrinsic Value
Price

See Also

What is Shanghai Runda Medical Technology Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
753.7m CNY

Based on the financial report for Sep 30, 2024, Shanghai Runda Medical Technology Co Ltd's Cash from Operating Activities amounts to 753.7m CNY.

What is Shanghai Runda Medical Technology Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
11%

Over the last year, the Cash from Operating Activities growth was 67%. The average annual Cash from Operating Activities growth rates for Shanghai Runda Medical Technology Co Ltd have been 83% over the past three years , 11% over the past five years .

Back to Top